NGS Best Practices for Developing Personalized Neoantigen Vaccines
Precision medicine strategies have changed how the industry is approaching the development of cancer treatment vaccines, from targeting tumor-specific mutations to harnessing the power of the immune system.
Advances in immuno-oncology research and next-generation sequencing (NGS) technologies has led to the discovery of a promising new class of immunogenic targets for personalized cancer vaccines called neoantigens. Neoantigens, peptide fragments expressed on the surface of tumor cells, can arise from any somatic tumor mutation and can be recognized by the immune system as “foreign”. However, because tumor mutations are as unique as fingerprints and exquisitely specific to each patient, the development of these truly personalized vaccines is difficult in terms of clinical trial implementation, bioinformatics prediction, and production.
Attendees will learn about best practices for personalized neoantigen vaccine development through:
- Optimized FFPE sample preparation for DNA and RNA sequencing
- Augmented whole exome and whole transcriptome sequencing
- Bioinformatics pipeline validation
- Designing rapid, patient-centric processes for vaccine clinical trials